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Abstract
Purpose: Molecular imaging of αvβ3 integrin has exhibited real potential to guide the appropriate
use of anti-angiogenic therapies. However, an incomplete understanding of the factors that
influence binding of αvβ3 integrin-specific radiotracers currently limits their use for assessing
response to therapy in cancer patients. This study identifies two fundamental factors that
modulate uptake of these radiotracers.
Procedures
Experiments were performed in prostate cancer (PC3) and glioblastoma (U87MG) cells, which
differentially express αvβ3 integrin. αvβ3 integrin-specific radiotracers were used to investigate
the effect of manipulating αvβ3 integrin expression or activation in cellular binding assays. β3
integrin and αvβ3 integrin expression were measured by western blotting and flow cytometry,
respectively. The effect of select pharmacological inhibitors on αvβ3 integrin activation and
expression was also determined.
Results: Radiotracer binding was proportional to αvβ3 integrin expression when it was decreased
(β3 knock-down cells) or increased, either using pharmacological inhibitors of cell signalling or
by culturing cells for different times. Studies with both small molecule and arginine–glycine–
aspartic acid (RGD)-based radiotracers revealed increased radiotracer binding after activation of
αvβ3 integrin with Mn
2+ or talin head domain. Moreover, inhibition of fundamental signalling
pathways (mitogen-activated protein kinase kinase (MEK), Src and VEGFR2) decreased
radiotracer binding, reflecting reduced αvβ3 integrin activity.
Conclusion: Binding of small molecule ligands and radiolabelled RGD peptides is modulated by
expression and activation status of αvβ3 integrin. αvβ3 integrin-specific radiotracers can provide
otherwise inaccessible information of the effect of signalling pathways on αvβ3 integrin. This has
significant implications for assessing response to anti-angiogenic therapies in clinical studies.
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Introduction
Tumour angiogenesis, the formation of new blood vessels, is a
hallmark of cancers that allows them to grow beyond a critical
size (2–3 mm) and metastatize to other organs [1]. The
angiogenic switch is triggered by tumour growth which creates
a hypoxic and acidic environment, promoting release of pro-
angiogenic factors such as vascular endothelial growth factor
(VEGF) and development of new blood vessels and endothelial
cell migration via integrins [1]. Therapeutic interventions that
target VEGF receptor 2 (VEGFR2) and integrins have been
evaluated as anti-angiogenic treatments, in accordance with
their key roles in the pathogenesis of tumour angiogenesis [2,
3]. However, effective imaging methods are needed to assess
whether tumours are actually responding to therapy, as the
efficacy of these treatments varies considerably between
tumour types and individual cancer patients.
The integrin family comprises 24 transmembrane receptors
formed by heterodimeric combinations of 18 α and 8 β
subunits. Each subunit comprises a short cytoplasmic domain,
a single transmembrane region and an extracellular domain.
Ligand binding to the extracellular domain allows integrins to
collate information about the extracellular environment [4, 5].
In addition, their cytoplasmic domains recruit intracellular
proteins such as talin, focal adhesion kinase (FAK) and Src,
leading to activation of canonical signalling pathways. As a
result of these interactions, integrins change their conformation
(i.e., undergo activation or inactivation) thereby driving tumour
angiogenesis [6, 7].
Molecular imaging of αvβ3 integrin offers a specific and
quantitative method of assessing the angiogenic potential of
tumours [8]. αvβ3 integrin is highly expressed on angiogenic
endothelial cells, involved in cell adhesion [9], cell migra-
tion and metastasis [2] and is a validated target for assessing
tumour angiogenesis [10]. Vitronectin and fibronectin bind
selectively to this receptor through an arginine–glycine–
aspartic acid (RGD) recognition sequence. Multiple positron
emission tomography (PET) radiotracers have been designed
based on the RGD motif to provide information on tumour
vascu la ture , wi th [1 8F]Galac to -RGD [11] and
[18F]Fluciclatide [12] being the best characterised.
Clinical studies [11–13] and mouse xenograft experiments
[14, 15] have both observed correlation between αvβ3 integrin
radiotracer uptake and baseline αvβ3 integrin expression,
supporting the use of these radiotracers as surrogate markers of
tumour angiogenic potential. Clinical studies have not yet
endorsed these radiotracers for assessing response to therapy,
despite their considerable potential in this role [16]. One key
reason is our incomplete understanding of how molecular
mechanisms influence radiotracer uptake; two preclinical studies
that have compared radiotracer binding with αvβ3 integrin
expression after anti-angiogenic therapy observed changes in
radiotracer binding that could not be attributed to altered αvβ3
expression [17, 18]. These reports strongly suggest that there are
uncharacterised factor(s) that can influence binding of these
radiotracers to cells/tumours.
In this study, we present conclusive evidence that binding
of αvβ3 integrin radiotracers to cells is influenced by both the
expression level and activation status of the target receptor.
Moreover, we also demonstrate that inhibition of fundamen-
tal signalling pathways (mitogen-activated protein kinase
kinase (MEK), Src and VEGFR2) influences αvβ3 integrin
radiotracer binding, resulting from a change in integrin
expression or reflecting decreased binding affinity. These
results broaden our understanding of the molecular changes
caused by anti-angiogenic treatment and have significant
implications for the use of αvβ3 integrin-specific radiotracers
in assessing response to therapy with these agents.
Materials and Methods
Reagents
All reagents were purchased from Sigma-Aldrich, unless
stated otherwise. UO126, PP-2, PF573228 and ZM323881
were from Bio-Techne. JetPRIME® transfection reagent was
from Source BioScience. Talin head domain (THD) con-
struct [19] was a kind gift from Prof David A. Calderwood
(Yale University, USA). Anti-αvβ3 integrin MAB1976
(LM609) was from Merck Millipore.
Cell Lines and Culture Conditions
All cell lines used in this study (prostate cancer (PC)3 and
U87MG) were authentic and purchased from ATCC. These
cell lines were specifically selected because they are known
to express moderate and high levels of αvβ3, respectively.
Cells were cultured in RPMI medium supplemented with
10 % FCS and 100 units/ml penicillin and 100 μg/ml
streptomycin under sterile conditions at 37 °C in a
humidified atmosphere containing 5 % CO2.
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Western Blotting
PC3 and U87MG cells were seeded at 0.35 × 106 cells/60 mm
plate. On the next day, cells were incubated with the specified
concentrations of UO126, ZM323881, PF573228 or PP2 for the
time indicated in each experiment. Cells were then washed with
PBS and scraped into lysis buffer (PBS containing 1mMsodium
orthovanadate, 1 mM sodium pyrophosphate, dithiothreitol and
protease inhibitors) and lysed by sonication. The total cell lysate
was used to ensure that all blots are fully representative of the
total cellular expression of each protein. The protein concentra-
tion in each sample was determined using the bicinchoninic acid
(BCA) assay. Western blotting was performed essentially using
the method indicated previously [20] with minor modifications
using primary antibodies against the following proteins: β3
integrin, Santa Cruz Biotechnology; extracellular signal regu-
lated kinase (ERK)1 and 2, pThr202/Tyr204 ERK 1 and 2,
VEGFR2, pTyr1175 VEGFR2, FAK, pTyr397 FAK, Src and
pTyr416 Src all from Cell Signalling; and green fluorescent
protein (GFP) MAB3580 from EMD Merck Millipore. After
incubation with primary antibody, membranes were washed in
PBS containing 0.1 % Tween 20, then incubated for 1 h with the
appropriate IR dye-conjugated secondary antibody (LI-COR)
diluted 1:10,000. Images were captured with an Odyssey® CLx
LI-COR imaging system. The densitometry of each protein band
was measured using Image Studio Lite.
Flow Cytometry Analysis of αvβ3 Integrin
Expression
PC3 and U87MG cells were seeded at 0.35 × 106 cells/60 mm
plate and grown for 72 h before the experiment, unless stated
otherwise. Cells were harvested from plates using cell dissoci-
ation reagent. αvβ3 cell surface expression was determined by
flow cytometry as previously described [21], using the LM609
antibody which binds selectively to αvβ3 integrin and detected
with an Alexa Fluor 488 secondary antibody. Data were
normalised against the untreated control, unless otherwise stated.
In Vitro Radiotracer Binding Assay
ZMPZAT71 is a novel triazole-based αvβ3 selective radio-
tracer with high αvβ3 binding affinity designed at the
University of Aberdeen [22]. Experiments were either
performed with [3H]ZMPZAT71 (synthesised by RC
TRITEC Ltd., Switzerland) or with [18F]FDR-Aoa-
c(RGDfK) [21]. Cells were seeded at 0.35 × 106 cells/
60 mm plate and grown for 72 h, unless stated otherwise. On
the day of the experiment, medium in each plate was replaced
with 3 ml fresh RPMI containing 0.1 % BSA. [3H]ZMPZAT71
was added at 0.5 MBq/plate and incubated for 30 min
(maximum radiotracer binding occurred within 30 min; data
not shown). Unbound radioactivity was removed by rinsing the
plates five times with ice-cold PBS. Cells were detached using
0.35 ml trypsin and neutralised with 0.35 ml RPMI. The
radioactivity present in 0.5 ml cell suspension was measured in
a TRICARB 2100 TR scintillation counter using ultima gold
scintillation fluid. The protein content in the remaining 0.2 ml
was measured using the BCA assay. Binding was expressed as
a function of radioactivity added per plate and normalised to
protein content. Radiotracer binding was performed in the
presence and absence of 10 μM Cyclo(Arg-Gly-Asp-D-Phe-
Lys) peptide (cRGDfK) (a non-radiolabelled cyclic peptide
known to bind selectively to αvβ3 integrin) [21]. Binding in the
absence of cRGDfK represents total binding. Binding in
presence of cRGDfK signifies non-specific binding. The
difference between total and non-specific binding denotes
specific binding (Fig. S1).
β3 Integrin Knock-Down Clones
U87MG cells with decreased αvβ3 integrin expression were
generated by transfecting cells with a small hairpin RNA
(shRNA) vector that specifically targets the integrin β3 subunit
(GeneCopoeia, Rockville, USA). Cells that stably incorporated
the shRNA vector were selected using puromycin. Individual
cells were selected and allowed to proliferate prior to analysis
for β3 knock-down by western blot and flow cytometry.
Talin Head Domain Transfection
U87MG and PC3 cells were seeded at 0.35 × 106 cells per
60 mm plate and incubated overnight. Cells were then
transfected with either a THD construct linked to GFP or
mock transfected, using JetPRIME reagent according to
manufacturer’s instructions. Transfection efficiency in both cell
lines was optimised by measuring the number of green cells at
various times (4–48 h) after THD-GFP transfection using an
EVOS AMG fluorescence digital inverted microscope.
Statistical Analysis
Microsoft Office Excel 2013 for Windows and GraphPad
Prism 5 were used for data processing, graph plotting and
statistical analysis. Statistical analysis of all data was performed
using two-tailed Student’s t test for two groups or one-way
analysis of variance (ANOVA) for three or more groups.
P values less than 0.05 were considered statistically significant.
Results
Radiotracer Binding Reflects αvβ3 Expression
Level
In U87MG cells, we observed that total β3 integrin
expression varied with cultivation time (Fig. 1a), more than
doubling between 24 h and 72 h after cell seeding (Fig. 1a).
Flow cytometry analysis confirmed that αvβ3 integrin cell
surface expression also increased with time (Fig. 1b). This
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trait was used initially to investigate the ability of
[3H]ZMPZAT71 to differentiate between different αvβ3
integrin expression levels. There was a clear time-
dependent increase in specific radiotracer binding (Fig. 1c),
reflecting the increased integrin expression (Fig. 1a, b).
αvβ3 knock-down clones were developed to confirm that the
radiotracer binds specifically to αvβ3 integrin. Since β3 integrin
forms heterodimers only with αv or αIIb [6], and cancer cells do
not express αIIb, αvβ3 knock-down clones can be generated by
downregulating β3 expression. Screening of multiple clones
identified clone 2F, which exhibited a 65 % reduction in β3
integrin (Fig. 1d, e) and a 44 % decrease in cell surface αvβ3
integrin expression (Fig. 1f). Radiotracer binding decreased by
66 % in the 2F clones (Fig. 1g), in line with the flow cytometry
and western blotting results (Fig. 1e, f). These data confirm that
downregulation of αvβ3 integrin produces a corresponding
decrease in radiotracer binding. Overall, a good correlation
(r2 = 0.91) was observed between radiotracer binding and αvβ3
integrin expression (Fig. S2).
Radiotracer Binding Is Influenced by αvβ3
Activation Status
It is well established that integrins are activated by Mn2+,
minimally affected by Mg2+ and inhibited by Ca2+ [23].
Therefore, the effect of divalent cations on radiotracer binding
was investigated to determine if the activation status of the
receptor can influence [3H]ZMPZAT71 binding. Divalent
cations were added to medium just prior to radiotracer, ensuring
that cells were not exposed to these stimuli for longer than
30 min. Indeed, in the presence of Mn2+, radiotracer binding
significantly increased in both PC3 and U87MG cell lines (Fig.
2a), despite there being no significant increase in cell surface
αvβ3 expression (data not shown). In contrast, Mg
2+ did not
increase radiotracer binding to either cell line, whereas Ca2+
decreased binding in both cell lines (Fig. 2a).
U87MG and PC3 cells were transfected with THD-GFP
construct, a specific activator of integrin proteins [24], to
determine whether the observed increase in radiotracer
binding (Fig. 2a) is specifically due to integrin activation.
Optimal transfection was observed after 24 h in PC3 cells
and 48 h in U87MG cells (Fig. S3). THD expression had no
significant effect on β3 integrin expression (Fig. 2b),
although a small increase (33 and 8 %, respectively) in cell
surface αvβ3 expression was observed in U87MG and PC3
cells (Fig. 2c). THD transfection produced a significant
increase in radiotracer binding in both cell lines; a 156 %
increase was observed in U87MG and a 297 % increase in
PC3 (Fig. 2d). These data are consistent with the activation
effect observed with Mn2+. Together, these two datasets
provide strong evidence that the activation status of αvβ3
Fig. 1. αvβ3 integrin radiotracer binding reflects αvβ3 integrin expression. U87MG cells were grown for 24, 48 or 72 h prior to
analysis (a–c). a Representative β3 integrin western blot with band quantification values stated. b Cell surface αvβ3 expression
by flow cytometry. c [3H]ZMPZAT71 radiotracer binding assay. d–g Analysis of U87MG cells with different β3 integrin levels
(untransfected parent, mock transfected and 2F β3 integrin knock-down). d Representative and e quantified β3 integrin western
blot. f Cell surface αvβ3 expression by flow cytometry. g [
3H]ZMPZAT71 radiotracer binding assay. Results are representative or
mean (± SD) of at least three independent experiments. Statistical analysis: *P G 0.05, **P G 0.01, ***P G 0.001.
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integrin has a significant influence on [3H]ZMPZAT71
binding. An equivalent experiment was therefore performed
with [18F]FDR-Aoa-c(RGDfK) [21] to ascertain whether
binding of RGD-based radiotracers is similarly influenced
by integrin activation. Indeed, the results clearly show that
THD transfection and Mn2+ both significantly increased
specific binding (Fig. 2e) of this class of radiotracers.
Correlation (r2 = 0.83) was observed between radiotracer
binding and αvβ3 integrin activation status (Fig. S2).
Increased Cell Surface Integrin Expression Does
Not Necessarily Enhance αvβ3 Integrin
Radiotracer Binding
αvβ3 integrin modulates signals from outside and inside
cells. However, the impact of many signalling pathways on
αvβ3 activation is uncertain [25]. UO126, a potent and
selective MEK1/2 inhibitor, was used to study the effect of
this signalling pathway on αvβ3 integrin. UO126 decreased
ERK 1/2 phosphorylation by approximately 90 % in
U87MG cells and resulted in both de-phosphorylation and
degradation of ERK in PC3 cells (Fig. 3a, b). While UO126
had no significant effect on β3 expression (Fig. 3b), αvβ3 cell
surface expression significantly increased by 90 % in
U87MG and 175 % in PC3 cells (Fig. 3c).
Radiotracer binding assays performed in the absence of
Mn2+ detected an 82 % increase in binding in U87MG cells
and a 42 % increase in PC3 cells after UO126 treatment
(Fig. 3d). As expected (Fig. 2a), inclusion of Mn2+ increased
radiotracer binding by 4.58- and 3.7-fold in UO126-treated
U87MG and PC3 cells, respectively (Fig. 3d). These results
demonstrate that an increase in cell surface αvβ3 expression
does not necessarily produce an equivalent increase in
radiotracer binding, but this can occur if the integrin
becomes activated. These data also indicate that αvβ3
integrin radiotracers can report on the activation status of
the receptor and that this is decreased by MEK1/2 inhibition.
Fig. 2. αvβ3 integrin radiotracer binding is increased by receptor activation. a [
3H]ZMPZAT71 radiotracer binding assay in the
absence of metal ions (control) or in the presence of 1 mM Mn2+, Mg2+ or Ca2+. b–e Cells were either mock transfected or
transfected with talin head domain (THD) linked to green fluorescent protein (GFP). b Western blot of β3 integrin and THD
expression. c Cell surface expression of αvβ3 by flow cytometry. d [
3H]ZMPZAT71 and e [18F]FDR-Aoa-c(RGDfK) radiotracer
binding assays. Results are representative or mean (± SD) of at least three independent experiments. Statistical analysis:
*P G 0.05, **P G 0.01, ***P G 0.001.
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Modulation of αvβ3 Integrin with Pharmacological
Inhibitors
In light of the finding that αvβ3 integrin radiotracers can
convey information on the activation status of its target
receptor, we investigated how select kinases involved in
αvβ3 signalling could modulate its activation status. Cluster-
ing of β3 integrins induces activation of Src via phosphor-
ylation of Tyr418 [26], stimulating tumour growth and lymph
node metastases [27]. The influence of Src was tested using
PP2, a selective Src inhibitor (Fig. S4). PP2 induced a 45 %
decrease in Src phosphorylation in both cell lines (Fig. 4a,
b). Negligible changes were observed in β3 integrin levels
(Fig. 4b) or cell surface αvβ3 integrin expression (Fig. 4c).
Radiotracer binding decreased by approximately 70 % in
PC3 and 40 % in U87MG cells (Fig. 4d), suggesting that Src
inhibition decreases αvβ3 integrin activation. In contrast,
inhibition of FAK phosphorylation using PF573228 had no
significant effect on αvβ3 integrin expression, localisation or
radiotracer binding (Fig. S5).
αvβ3 integrin activation is dependent on VEGFR2 in
endothelial cells [28]. ZM323881, a potent and selective
VEGFR2 inhibitor, was used to investigate the role of this
receptor on αvβ3 integrin expression and activation.
ZM323881 treatment decreased pTyr1175 VEGFR2 by
50 % in PC3 but had no significant effect in U87MG cells,
likely due to the lower baseline VEGFR2 phosphorylation
level detected. No significant changes in β3 integrin
expression (Fig. 5a, b) or αvβ3 integrin expression (Fig. 5c)
were observed in either cell line. A 40 % decrease in
radiotracer binding was observed in PC3 cells, but no
significant change was detected in U87MG cells (Fig. 5d).
Hence, downregulation of VEGFR2 signalling is clearly
linked to decreased αvβ3 integrin activation in cells.
Importantly, inclusion of Mn2+ after cells had been treated
with VEGFR2 (or Src) inhibitors significantly increased
radiotracer binding (data not shown). This demonstrates that
the receptor still retains the capacity to be activated and that
the decreased radiotracer binding after drug treatment is due
to reduced receptor activation status.
The understanding that αvβ3 integrin radiotracer binding
is influenced by both receptor expression and activation is an
important advance. Table 1 summarises the effect of each
treatment used herein on integrin expression and activation.
Expressing radiotracer binding as a function of cell surface
αvβ3 integrin expression produces a new metric that permits
a direct comparison of the effect of diverse intracellular and
extracellular treatments on αvβ3 integrin activation status.
Normalised αvβ3 integrin radiotracer binding after each
treatment was expressed as a function of the normalised cell
Fig. 3. ERK inhibition increases cell surface expression of αvβ3 but decreases its activation status. Cells were treated with
25 μM UO126 or vehicle for 24 h. a Representative and b quantitative western blots analysis of ERK, pERK and β3 integrin. c
Cell surface αvβ3 expression by flow cytometry. d [
3H]ZMPZAT71 radiotracer binding assay performed in the presence (+) and
absence (−) of Mn2+. Results are representative or mean (± SD) of at least three independent experiments. Statistical analysis:
*P G 0.05, **P G 0.01, ***P G 0.001.
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surface αvβ3 integrin expression. The resulting ratio provides
a measure of αvβ3 integrin activation compared to control
cells. A ratio 91 signifies activation, whereas a ratio G1
represents inhibition.
Discussion
There is an urgent need for sensitive, accurate and robust
imaging methods to report on tumour angiogenesis since the
current success rate of anti-angiogenic therapies varies
considerably between both tumour types and individual
patients. αvβ3 integrin is well recognised as an appropriate
target for providing pertinent molecular imaging informa-
tion, as the receptor is highly expressed on angiogenic
endothelial cells and a validated target for assessing tumour
angiogenesis [10]. Correlation between baseline αvβ3
integrin expression and binding of αvβ3 integrin-targeted
radiotracers has been established in multiple preclinical and
clinical studies [11–15], demonstrating their suitability to
detect tumours with angiogenic potential. On the other hand,
while multiple preclinical studies have utilised αvβ3 integrin
radiotracers to assess response to anti-angiogenic therapies
[17, 18, 29–32], most have either consciously not reported
correlation between radiotracer binding and receptor expres-
sion [29, 30, 32] or have reported a lack of correlation [17,
18]. This strongly suggests that there are uncharacterised
factor(s) that can influence radiotracer uptake in cells/
tumours. In this study, we directly demonstrate for the first
time that radiotracer binding can be attributed to both αvβ3
integrin activation status and expression, providing a
rationale for the documented discrepancy between radio-
tracer binding and receptor expression after therapy.
Severa l l ines of ev idence demons t ra te tha t
[3H]ZMPZAT71 binds specifically to αvβ3 in cells and the
magnitude of binding reflects receptor expression. Firstly, in
U87MG cells, [3H]ZMPZAT71 binding increased in a
temporal manner in parallel with αvβ3 integrin (Fig. 1).
Secondly, in β3 integrin knock-down cells, proportionate
decreases in radiotracer binding and receptor knock-down
were observed (Fig. 1). Finally, UO126 treatment produced
increases in both cell surface αvβ3 integrin expression and
radiotracer binding when Mn2+ was present (Fig. 3). These
results are in agreement with previous studies showing a
direct relationship between αvβ3 integrin expression and a
αvβ3-targeted radiotracer uptake in xenograft [14, 15] and
clinical studies [11–13]. Taken together, these data provide
strong evidence of a direct relationship between baseline
receptor expression and binding of multiple distinct αvβ3
integrin radiotracers.
Significant increases in αvβ3 integrin radiotracer binding
were observed in both cell line models after integrins were
activated via two independent mechanisms (Fig. 2). Mn2+
Fig. 4. Src inhibition decreases αvβ3 integrin radiotracer binding. Cells were treated with 10 μM PP2 or vehicle for 1 h. a
Representative and b quantitative western blot analysis of Src, pSrc and β3 integrin. c Cell surface αvβ3 expression by flow
cytometry. d [3H]ZMPZAT71 radiotracer binding assay performed in the absence of Mn2+. Results are representative or mean (±
SD) of at least three independent experiments. Statistical analysis: *P G 0.05, **P G 0.01, ***P G 0.001.
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binds to metal ion-dependent adhesion site (MIDAS) on the
β subunit extracellular domain [7], producing a conforma-
tion change that increases αvβ3 affinity/avidity for ligands
[33]. The opposite effect was observed with Ca2+,
confirming that integrin activity can also be decreased. Talin
head domain selectively activates integrins by binding to
their intracellular domain and changing their conformation
[34]. The data presented herein indicate that radiotracer
binding is sensitive to integrin activation induced either by
extracellular or intracellular activation. Indeed, this is
apparently a class effect since binding of two distinct αvβ3
integrin binding radiotracers, [3H]ZMPZAT71 and
[18F]FDR-Aoa-(RGDfK), was enhanced. Taken together,
these two datasets provide very strong evidence that
radiotracer binding is sensitive to integrin activation status
in cells and that these radiotracers can report on αvβ3 integrin
activation status. To our knowledge, this is the first study to
directly demonstrate this.
Two xenograft studies have also reported changes in
binding of αvβ3 integrin radiotracers that cannot be
accounted for by altered αvβ3 integrin expression [17, 18].
The most likely interpretation of the study data is that αvβ3
integrin activation is also modulated in vivo. In the first
study, an U87MG xenograft was treated with the Src
inhibitor dasatinib. [64Cu]-DOTA-c(RGDfK) radiotracer
uptake was decreased in the absence of any effect on total
or cell surface αvβ3 integrin expression [18]. This result can
be accounted for by the decrease in αvβ3 integrin activation
caused by Src inhibitors (Fig. 4d and Table 1). The second
study involved an A431 xenograft treated with bevacizumab.
Table 1. Expressing αvβ3 integrin radiotracer binding as a function of cell surface expression produces a measure of integrin activation
Relative
αvβ3expression
Relative radiotracer
binding
Activation ratio
(binding/expression)
Effect on
αvβ3activity
Cell line PC3 U87MG PC3 U87MG PC3 U87MG −
Treatment
Control 100 100 100 100 1.00 1.00 −
Mn2+ 100 100 288 227 2.88 2.27 Activation
THD 108 133 397 256 3.68 1.92 Activation
UO126 274 190 142 182 0.52 0.95 Inhibition
UO126+Mn2+ 274 190 526 834 1.92 4.39 Activation
PP2 92 115 27 66 0.29 0.57 Inhibition
PF573228 102 114 124 102 1.22 0.89 No apparent change
ZM323881 99 110 58 95 0.59 0.86 Inhibition in PC3 cells
Bold text has been used to represent increased radiotracer binding and italic text to highlight decreased radiotracer binding
Fig. 5. VEGFR2 inhibition decreases αvβ3 integrin radiotracer binding. Cells were treated with 1 μM ZM323881 for 1 h or
vehicle for 1 h. a Representative and b quantitative western blot analysis of VEGFR2, pVEGFR2 and β3 integrin. c Cell surface
αvβ3 expression by flow cytometry. d [
3H]ZMPZAT71 radiotracer binding assay performed in the absence of Mn2+. Results are
representative or mean (± SD) of at least three independent experiments. Statistical analysis: *P G 0.05, **P G 0.01, ***P G 0.001.
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Increased [68Ga]-NODAGA-c(RGDfK) binding was ob-
served despite a 50 % decrease in αvβ3 integrin expression
[17]. The authors attributed the increased binding to integrin
activation and/or enhanced tumour perfusion. On the other
hand, an MDA-MB-435 xenograft study showed that
[18F]FPPRGD2 binding and αvβ3 integrin staining both
decreased after treatment with ZD4190, a potent inhibitor
of VEGFR1 and VEGFR2 inhibitor [31], in agreement with
the observed correlation between baseline integrin expres-
sion and radiotracer binding (Fig. 1) [11, 12, 14, 15]. Other
in vivo studies have not assessed αvβ3 integrin expression
[29, 30, 32] but have demonstrated decreased radiotracer
binding after treatment with VEGFR2 inhibitors. In light of
the data presented in Fig. 5, it seems likely that the observed
decrease in radiotracer binding could be attributed to
decreased αvβ3 integrin activation.
Prior to this study, the effect of individual cell signalling
proteins on αvβ3 integrin activation was not clear [4, 25].
Our finding that αvβ3 integrin binding radiotracers can report
on αvβ3 integrin activation status allows this otherwise
inaccessible information to be directly revealed. The results
clearly demonstrate that inhibition of MEK1/2, Src and
VEGFR2, but not FAK, decreases αvβ3 integrin activation
(Table 1). The effect of the Src inhibitor is in line with a
U87MG xenograft study that intimates that the Src inhibitor
dasatinib may decrease αvβ3 integrin activation [18]. It is
well established that Src family kinases are activated by
integrins through the β3 cytoplasmic tail. The data presented
herein demonstrate that Src also plays a role in integrin
activation, although it is not clear if this is a direct or indirect
effect. The inhibitory effect of VEGFR2 inhibitors shown
here (Fig. 5) provides a molecular rationale for several
xenograft studies that have shown reduced radiotracer
uptake [30–32] after VEGFR2 inhibitor treatment.
VEGFR2-αvβ3 integrin association is important for full
VEGFR2 activity and subsequent activation of intracellular
signalling pathways [2]. As VEGFR2 autophosphorylation is
crucial for VEGFR2-αvβ3 interaction, VEGFR2 inhibitors
can reduce αvβ3 integrin activation. The magnitude of this
effect appears to be dependent on the basal level of
VEGFR2 phosphorylation, since an inhibitory effect was
not observed in U87MG cells, which contain lower levels of
VEGFR2 phosphorylation. Increased cell surface expression
of αvβ3 and other integrin subunits following UO126
treatment have been reported previously [35, 36]. However,
its inhibitory effect on αvβ3 integrin activation has not been
documented. One possibility is that the increased cell surface
expression of αvβ3 integrin is a direct consequence of the
decreased integrin activity.
The data reported herein have significant implications for
assessing response to anti-angiogenic therapies in clinical
studies. Studies need to consider both the expression level
and activation status of integrins. This will make data
interpretation more challenging but also raises new possibil-
ities. Challenges include the confounding factors arising
from combining anti-angiogenics with standard
chemotherapies, which could either alter the expression
level or activation status of αvβ3 integrin. Opportunities
include the possibility of studying binding of αvβ3 integrin
radiotracers to either the tumour vasculature or tumour cells
that express αvβ3 integrin, to assess the efficacy of Src,
VEGFR2 and MEK inhibitors. This study provides valuable
insight into the molecular mechanism of modulation of
integrin signalling pathways in response to anti-cancer
agents, but further work is required to take full advantage
of these new opportunities to use αvβ3 integrin-targeted
radiotracers for assessing response to therapy.
Conclusion
Binding of radiotracers to cells corresponds with both
changes in αvβ3 integrin expression and activation status.
These results are applicable to both RGD-labelled peptides
and small molecule antagonists of αvβ3 integrin, indicating
that this is a general effect, pertinent to this entire class of
radiotracers. These findings provide a rationale for the
documented discrepancy between radiotracer binding and
receptor expression after therapy in several xenograft studies
and have important consequences for imaging αvβ3 integrin
in vivo. Some tumours that express this receptor may not
have significant uptake of these radiotracers if the receptors
are not activated. Moreover, these radiotracers appear to
have significant potential to assess response to treatment
with a range of classes of anti-cancer drugs (e.g., ERK, Src
and VEGFR2 inhibitors) by providing early guidance on the
efficacy of these agents in clinical studies.
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